Any current/future new fundraising through debt or equity?

The company is currently debt-free with strong cash positions. They do not utilize any working capital limits except for letters of credit and bank guarantees. No borrowings have been utilized in the last six months. There is no mention of any planned fundraising through debt or equity in the current or near future. The company appears focused on organic growth funded through internal accruals and careful capex planning (INR 100 crores planned for FY25).

Any current/future capex/capital investment/strategic investment?

Capex of about INR 100 crores anticipated in FY25, mainly for the Ambernath facility and new Module E. Module E is expected to be commissioned by end of the current month, with commercial production starting by Q2 FY25. Ambernath facility is also scheduled to be ready by Q2 FY25 to expand CMO and CDMO activities. An additional capex of approximately INR 75 crores for Ambernath has already been spent. Debottlenecking activities are ongoing to enhance capacity at the current product basket. The new capacities at Lote will reach around 1020 KL, and Ambernath will add approximately 200 KL. Capex a

Future growth expectations in sales/revenue/volumes?

The company targets 20%+ annual revenue growth driven by a blended portfolio including existing products, new product launches, and CMO/CDMO activities. Peak revenue from the DSM contract is expected around INR60-70 crores with anticipated 20-25 metric tons supply in FY '25. New product launches in regulated markets, including anaesthetic, anti-diabetic, and anti-anxiety categories, are expected to significantly contribute starting FY '25. CMO/CDMO segment is forecasted to contribute 18-20% of total revenue by FY '27, with Amarnath facility advancing capacity. The oral cancer detection kit is

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets 20%+ revenue growth year-on-year, aiming for around INR 1,000 crores revenue by FY27. EBITDA margin guidance is maintained at a steady 28%-30%, with potential for improvement through new premium-margin projects. CMO/CDMO business is expected to contribute 18%-20% of total revenue by FY27, offering better margin profiles. New product launches in regulated markets and expanded CMO/CDMO capabilities (including Ambernath and module E facilities) are key growth drivers. Clinical trials for the oral cancer detection kit are underway; product launch anticipated in about 2 years, a

Current/ Expected Orderbook/ Pending Orders?

The company has several advanced-stage CMO projects with volume commitments and signed binding contracts expected to scale up over the next 2-3 years. The DSM contract is a significant existing order, with expected material supply of 20-25 metric tons in FY '25, generating peak revenues of INR 60-70 crores. The Ambernath facility capex is underway and expected to contribute to capacity but peak revenue generation from Ambernath is anticipated later than FY '25. Registrations in Brazil have opened up a sizable market expected to add around INR 200 crores to the topline over the next 3 yea

Supriya Lifesci.Q4 FY24Pharmaceuticals & Biotechnology

Supriya Lifesci. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹931P/E: 39.9Market Cap: ₹7.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company targets 20%+ annual revenue growth driven by a blended portfolio including existing products, new product launches, and CMO/CDMO activities.
Peak revenue from the DSM contract is expected around INR60-70 crores with anticipated 20-25 metric tons supply in FY '25.
New product launches in regulated markets, including anaesthetic, anti-diabetic, and anti-anxiety categories, are expected to significantly contribute starting FY '25.
CMO/CDMO segment is forecasted to contribute 18-20% of total revenue by FY '27, with Amarnath facility advancing capacity.
The oral cancer detection kit is scheduled for launch in ~2 years following clinical trials.
Capacity utilization currently at ~86%, with new modules (Amarnath and Module E) commissioning by Q2 FY '25; full-scale production to take 2-3 years.
Regulated market share is increasing, stabilizing revenue with diversified product basket mitigating seasonality effects.

Margin guidance

Category 3

The company targets 20%+ revenue growth year-on-year, aiming for around INR 1,000 crores revenue by FY27.
EBITDA margin guidance is maintained at a steady 28%-30%, with potential for improvement through new premium-margin projects.
CMO/CDMO business is expected to contribute 18%-20% of total revenue by FY27, offering better margin profiles.
New product launches in regulated markets and expanded CMO/CDMO capabilities (including Ambernath and module E facilities) are key growth drivers.
Clinical trials for the oral cancer detection kit are underway; product launch anticipated in about 2 years, adding future revenue streams.
Operational efficiencies have improved working capital cycles and reduced borrowing needs, positively impacting profitability.
Stable and improving margins expected due to better product mix and regulated market focus.
Overall profits and EPS are expected to grow in line with revenue and margin expansions driven by strategic investments and product pipeline.

See what Supriya Lifesci. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company is currently debt-free with strong cash positions.
They do not utilize any working capital limits except for letters of credit and bank guarantees.
No borrowings have been utilized in the last six months.
There is no mention of any planned fundraising through debt or equity in the current or near future.
The company appears focused on organic growth funded through internal accruals and careful capex planning (INR 100 crores planned for FY25).

Order book

The company has several advanced-stage CMO projects with volume commitments and signed binding contracts expected to scale up over the next 2-3 years.
The DSM contract is a significant existing order, with expected material supply of 20-25 metric tons in FY '25, generating peak revenues of INR 60-70 crores.
The Ambernath facility capex is underway and expected to contribute to capacity but peak revenue generation from Ambernath is anticipated later than FY '25.
Registrations in Brazil have opened up a sizable market expected to add around INR 200 crores to the topline over the next 3 years.
The company is scaling up new products and expecting commercial production startups imminently for validation batch supplied CMO opportunities.
Overall confidence expressed on achieving INR 1000 crores topline with ~18-20% from CMO/CDMO by FY '27, supported by a diversified and de-risked product portfolio.

See what Supriya Lifesci. management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex of about INR 100 crores anticipated in FY25, mainly for the Ambernath facility and new Module E.
Module E is expected to be commissioned by end of the current month, with commercial production starting by Q2 FY25.
Ambernath facility is also scheduled to be ready by Q2 FY25 to expand CMO and CDMO activities.
An additional capex of approximately INR 75 crores for Ambernath has already been spent.
Debottlenecking activities are ongoing to enhance capacity at the current product basket.
The new capacities at Lote will reach around 1020 KL, and Ambernath will add approximately 200 KL.
Capex and capacity expansion aim to support the scaling up of CMO/CDMO projects, expecting 18-20% of revenue from these by FY27.

Track Supriya Lifesci. — get its next earnings analysis in your feed

How does Supriya Lifesci. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSupriya Lifesci.

Rev 2Mar 3

See where Supriya Lifesci. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Supriya Lifesci. rank in Pharmaceuticals & Biotechnology?

Compare Supriya Lifesci. against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Supriya Lifesci.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →